Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.51 |
| ▸ | RARB | P10826 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659360 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL338316 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1609987 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1611001 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL309133 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL987954 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL9121701 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL263776 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL988767 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1610778 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 571 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964602-A | Benzothiophene ketone derivative and preparation method and application thereof | 广州医科大学 | 2024-05-03 | — | — | CN | claimed |
| EP-3476845-B1 | ORGANIC THIN-FILM TRANSISTOR, ORGANIC SEMICONDUCTOR FILM, COMPOUND, ORGANIC-THIN-FILM-TRANSISTOR COMPOSITION, AND ORGANIC-THIN-FILM-TRANSISTOR MANUFACTURING METHOD | FUJIFILM CORP (JP) | 2021-07-21 | — | — | EP | claimed |
| US-8809010-B2 | Method for prophylactic treatment of alzheimer's disease using inhibitors of glutaminyl cyclase and glutamate cyclases | PROBIODRUG AG (DE) | 2014-08-19 | — | — | US | claimed |
| EP-2077992-B1 | INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2013-08-14 | — | — | EP | claimed |
| US-8338120-B2 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor such as 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; dementia | PROBIODRUG AG (DE) | 2012-12-25 | — | — | US | claimed |
| EP-2481408-A2 | New use of glutaminyl cyclase inhibitors | Probiodrug AG (DE) | 2012-08-01 | — | — | EP | claimed |
| US-20120184518-A1 | METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2012-07-19 | — | — | US | claimed |
| US-7960569-B2 | Such as 3-(2-isopropylphenyl)-N-phenyl-1H-indol-1-carboxamide; purinergic receptors (P2Y1) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | claimed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | claimed |
| US-7732162-B2 | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases | PROBIODRUG AG (DE) | 2010-06-08 | — | — | US | claimed |
| EP-0766665-A2 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-04-09 | — | — | EP | claimed |
| EP-0766664-A2 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-04-09 | — | — | EP | claimed |
| WO-1995035275-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| WO-1995035276-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| WO-1995011898-A1 | CONDENSED PYRIDINE TYPE MEVALONOLACTONE INTERMEDIATE AND PROCESS FOR ITS PRODUCTION | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1995-05-04 | — | — | WO | claimed |
| EP-0339358-B1 | Pyrazolopyridine type mevalonolactones | NISSAN CHEMICAL IND LTD (JP) | 1994-07-13 | — | — | EP | claimed |
| EP-0267585-B1 | FLUOROALKANE DERIVATIVE, ITS COMPOSITION AND LIQUID CRYSTAL DEVICE USING SAME | CANON KABUSHIKI KAISHA (JP) | 1993-09-15 | — | — | EP | claimed |
| EP-0535548-A1 | Inhibitor of atherosclerotic intimal thickening | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1993-04-07 | — | — | EP | claimed |
| EP-0339358-A1 | Pyrazolopyridine type mevalonolactones | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-11-02 | — | — | EP | claimed |
| WO-1989010365-A1 | PYRAZOLOPYRIDINE TYPE MEVALONOLACTONES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1989-11-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184518-A1 | METHODS OF TREATING OR PREVENTING AN INFLAMMATORY DISEASE OR CONDITION USING GLUTAMINYL CYCLASE INHIBITORS | QPCT, GGCT, GLUL | NR5A1 2407/4885LTA4H 1376/4885TP53 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.